Rayze Bio, Inc. RYZB
We take great care to ensure that the data presented and summarized in this overview for RayzeBio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RYZB
Top Purchases
Top Sells
About RYZB
Insider Transactions at RYZB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 26
2024
|
Viking Global Investors LP |
SELL
Other acquisition or disposition
|
Indirect |
13,285,400
-100.0%
|
-
|
|
Feb 26
2024
|
Richard A. Heyman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
367,446
-100.0%
|
$22,781,652
$62.5 P/Share
|
|
Feb 26
2024
|
Maha Katabi |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,419,528
-100.0%
|
$150,010,736
$62.5 P/Share
|
|
Feb 26
2024
|
Susan Moran CHIEF MEDICAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
323,455
-100.0%
|
$20,054,210
$62.5 P/Share
|
|
Feb 26
2024
|
Kenneth Song PRESIDENT AND CHIEF EXECUTIVE |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,622,968
-100.0%
|
$100,624,016
$62.5 P/Share
|
|
Feb 26
2024
|
Arvind Kush CHIEF FINANCIAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
78,433
-100.0%
|
$4,862,846
$62.5 P/Share
|
|
Jan 22
2024
|
Susan Moran CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,875
+8.73%
|
$92,625
$3.24 P/Share
|
|
Sep 19
2023
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,857,706
+32.61%
|
-
|
|
Sep 19
2023
|
Maha Katabi |
BUY
Open market or private purchase
|
Indirect |
472,222
+16.33%
|
$8,499,996
$18.0 P/Share
|
|
Sep 19
2023
|
Maha Katabi |
BUY
Conversion of derivative security
|
Indirect |
1,947,306
+50.0%
|
-
|
|
Sep 19
2023
|
Viking Global Investors LP |
BUY
Open market or private purchase
|
Indirect |
2,777,778
+18.39%
|
$50,000,004
$18.0 P/Share
|
|
Sep 19
2023
|
Viking Global Investors LP |
BUY
Conversion of derivative security
|
Indirect |
10,507,622
+41.59%
|
-
|
|
Sep 19
2023
|
Ven Bio Global Strategic Fund Iii, L.P. |
BUY
Conversion of derivative security
|
Direct |
5,158,162
+24.4%
|
-
|
|
Sep 19
2023
|
Wellington Biomedical Innovation Master Investors (Cayman) Ii L.P. |
BUY
Conversion of derivative security
|
Direct |
1,557,846
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
24.3M
Shares
From
8
Insiders
| Conversion of derivative security | 21M shares |
|---|---|
| Open market or private purchase | 3.25M shares |
| Exercise of conversion of derivative security | 30.9K shares |
Sell / Disposition
18.1M
Shares
From
6
Insiders
| Other acquisition or disposition | 13.3M shares |
|---|---|
| Sale (or disposition) back to the issuer | 4.81M shares |